WO2021049830A1 - Ykl-40 표적 인간 단일클론항체 - Google Patents
Ykl-40 표적 인간 단일클론항체 Download PDFInfo
- Publication number
- WO2021049830A1 WO2021049830A1 PCT/KR2020/012036 KR2020012036W WO2021049830A1 WO 2021049830 A1 WO2021049830 A1 WO 2021049830A1 KR 2020012036 W KR2020012036 W KR 2020012036W WO 2021049830 A1 WO2021049830 A1 WO 2021049830A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- seq
- amino acid
- monoclonal antibody
- acid sequence
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
Definitions
- the present invention is a monoclonal antibody specifically binding to YKL-40, a nucleic acid molecule encoding the same, a pharmaceutical composition for preventing or treating cancer comprising the monoclonal antibody, and for diagnosis of cancer comprising the monoclonal antibody It relates to the composition.
- Antibodies are immune proteins that bind to specific antigens. In most mammals, including humans and mice, antibodies are formed by pairing heavy and light chain polypeptides. Each chain consists of two regions called the variable region (Fv) and the constant region (Fc). The light and heavy chain variable regions contain the antigen-binding determinant of the molecule and are involved in binding to the target antigen.
- the constant region defines a group of antibodies (or the same reference sample type) (e.g., IgG) and is involved in the binding of a number of Fc receptors and Fc ligands, conferring a series of important functional properties called effector action. do. Antibodies are used as potent therapeutics because of the properties of several important antibodies, such as, for example, specificity for the target, the ability to mediate immune mechanisms, and long serum half-life.
- Phage display technology was first developed in 1990 by the Medical Research Council in the UK.A human antibody library was prepared and expressed on the surface of bacteriophage in the form of antibody fragments (Fab, ScFv) to select antibody clones for specific antigens. It is a skill to do. The possibility of screening almost all types of human recombinant monoclonal antibodies that specifically react with antigens from a single pot antibody library system has been proposed, and this is a variety of antibodies that can be applied to in vivo diagnosis or treatment when phage display antibody technology is used. Fragments (Fab or ScFv form) can be obtained.
- An object of the present invention is to provide a monoclonal antibody that specifically binds to YKL-40.
- Another object of the present invention is to provide a nucleic acid molecule encoding the monoclonal antibody.
- Another object of the present invention is to provide a recombinant expression vector containing the nucleic acid molecule.
- Another object of the present invention is to provide a transformant transformed with the recombinant expression vector.
- Another object of the present invention is to provide a pharmaceutical composition for preventing or treating cancer comprising the monoclonal antibody as an active ingredient.
- Another object of the present invention is to provide a composition for diagnosis of cancer comprising the monoclonal antibody as an active ingredient.
- the present invention provides a monoclonal antibody that specifically binds to YKL-40.
- the monoclonal antibody comprises (a) CDR1 consisting of the amino acid sequence of SEQ ID NO: 5; CDR2 consisting of the amino acid sequence of SEQ ID NO: 6; And a heavy chain variable region comprising CDR3 consisting of the amino acid sequence of SEQ ID NO: 7; And (b) a CDR1 consisting of the amino acid sequence of SEQ ID NO: 11; CDR2 consisting of the amino acid sequence of SEQ ID NO: 12; And a light chain variable region comprising a CDR3 consisting of the amino acid sequence of SEQ ID NO: 13, or (a) a CDR1 consisting of the amino acid sequence of SEQ ID NO: 8; CDR2 consisting of the amino acid sequence of SEQ ID NO: 9; And a heavy chain variable region comprising a CDR3 consisting of the amino acid sequence of SEQ ID NO: 10; And (b) CDR1 consisting of the amino acid sequence of SEQ ID NO: 14, and CDR2 consisting of the amino acid sequence of the amino acid sequence of SEQ
- the monoclonal antibody comprises (a) a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 1; And (b) a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 3, or (a) a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 2; And (b) a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 4.
- the monoclonal antibody may be a humanized antibody.
- the present invention provides a nucleic acid molecule encoding the monoclonal antibody.
- the nucleic acid molecule is (a) CDR1 consisting of the nucleotide sequence of SEQ ID NO: 21; CDR2 consisting of the nucleotide sequence of SEQ ID NO: 22; And a heavy chain variable region comprising a CDR3 consisting of the nucleotide sequence of SEQ ID NO: 23; And (b) CDR1 consisting of the nucleotide sequence of SEQ ID NO: 27; CDR2 consisting of the nucleotide sequence of SEQ ID NO: 28; And a light chain variable region comprising a CDR3 consisting of the nucleotide sequence of SEQ ID NO: 29, or (a) a CDR1 consisting of the nucleotide sequence of SEQ ID NO: 24; CDR2 consisting of the nucleotide sequence of SEQ ID NO: 25; And a heavy chain variable region comprising a CDR3 consisting of the nucleotide sequence of SEQ ID NO: 26; And (b) CDR1 consisting of the nu
- the nucleic acid molecule comprises: (a) a heavy chain variable region consisting of the nucleotide sequence of SEQ ID NO: 17; And (b) a light chain variable region consisting of the nucleotide sequence of SEQ ID NO: 19, or (a) a heavy chain variable region consisting of the nucleotide sequence of SEQ ID NO: 18; And (b) a light chain variable region consisting of the nucleotide sequence of SEQ ID NO: 20.
- the present invention provides a recombinant expression vector containing the nucleic acid molecule.
- the present invention provides a transformant transformed with the recombinant expression vector.
- the present invention provides a pharmaceutical composition for preventing or treating cancer comprising the monoclonal antibody as an active ingredient.
- the cancer is breast cancer, colon cancer, lung cancer, stomach cancer, liver cancer, blood cancer, bone cancer, pancreatic cancer, skin cancer, brain cancer, uterine cancer, nasopharyngeal cancer, laryngeal cancer, head and neck cancer, colon cancer, ovarian cancer, rectal cancer , Colon cancer, vaginal cancer, small intestine cancer, endocrine cancer, thyroid cancer, parathyroid cancer, ureteral cancer, urethral cancer, prostate cancer, bronchial cancer, bladder cancer, kidney cancer, and bone marrow cancer.
- the present invention provides a composition for diagnosis of cancer comprising the monoclonal antibody as an active ingredient.
- the cancer is breast cancer, colon cancer, lung cancer, stomach cancer, liver cancer, blood cancer, bone cancer, pancreatic cancer, skin cancer, brain cancer, uterine cancer, nasopharyngeal cancer, laryngeal cancer, head and neck cancer, colon cancer, ovarian cancer, rectal cancer , Colon cancer, vaginal cancer, small intestine cancer, endocrine cancer, thyroid cancer, parathyroid cancer, ureteral cancer, urethral cancer, prostate cancer, bronchial cancer, bladder cancer, kidney cancer, and bone marrow cancer.
- YKL-40 of the present invention is related to the proliferation and metastasis of cancer, and the monoclonal antibody specifically binding to YKL-40 has the effect of inhibiting the proliferation and metastasis of cancer. It can be usefully used in the diagnosis, prevention or treatment of.
- Figure 1a is a schematic diagram showing the process of selecting an antibody showing significant binding ability with human YKL-40 through phage display
- 1b to 1d are panning titration results for Fab-I, Fab-II and scFv, respectively Is shown.
- 2A and 2B show antibodies against 7 human YKL-40 selected from phage display.
- Figure 3a is a schematic diagram showing the process of selecting an antibody showing significant binding ability to mouse YKL-40 through phage display
- 3b to 3d are panning titration results for Fab-I, Fab-II and scFv, respectively Is shown.
- Figure 4 shows antibodies against 6 mouse YKL-40 selected from phage display.
- 5A to 5C show SDS-PAGE results and measurement results of IgG production in order to confirm IgG production from six clones (H1, H2, H4, H5, H6 and H7) having a human YKL-40 antibody. .
- 6A and 6B show the results of size exclusion chromatography (SEC) for six human YKL-40 antibodies.
- 8A and 8B show SDS-PAGE results and measurement results of IgG production in order to confirm IgG production from four clones (M2, M3, M4 and M5) having a mouse YKL-40 antibody.
- 9A and 9B show the results of size exclusion chromatography (SEC) for four mouse YKL-40 antibodies.
- FIG. 10 shows the results of measuring EC50 values for four mouse YKL-40 antibodies through ELISA.
- 11A and 11B show whether the human YKL-40 antibody 3A10-F1 (H1) and the mouse YKL-40 antibody 4E3-F2 (M3) clone cross-link to the human YKL-40 antigen and the mouse YKL-40 antigen. It shows the results confirmed through ELISA.
- Figures 12a to 12c are human YKL-40 antibody 3A10-F1 (H1) and mouse YKL-40 antibody 4E3-F2 (M3) to measure the antigen affinity of the human YKL-40 antigen and mouse YKL-40 antigen It shows one result.
- 13A to 13D show the results of measuring the migrated cell number after treating the human YKL-40 antibodies H1, H2, H4, H5, H6 and H7 as candidate antibodies to the A549 cell line and the H460 cell line. Is shown.
- 14A to 14D show the results of measuring the number of migrated cells after treatment with the mouse YKL-40 antibodies M2, M3, M4 and M5 as candidate antibodies on the A549 cell line and the H460 cell line.
- antibody includes immunoglobulin molecules immunologically reactive with a specific antigen, and includes both polyclonal antibodies and monoclonal antibodies.
- the term includes forms produced by genetic engineering such as chimeric antibodies (eg, humanized murine antibodies) and heterologous antibodies (eg, bispecific antibodies).
- monoclonal antibody refers to a highly specific antibody directed against a single antigenic site as a term known in the art. Typically, unlike polyclonal antibodies, which contain different antibodies directed against different epitopes (antigen determinants), monoclonal antibodies are directed against a single determinant on the antigen. Monoclonal antibodies have the advantage of improving the selectivity and specificity of diagnostic and analytical assays using antigen-antibody binding, and also have another advantage of not being contaminated by other immunoglobulins because they are synthesized by hybridoma culture. .
- immunoglobulins have a heavy and light chain, each of which comprises a constant region and a variable region (the region is also known as a “domain”).
- the light chain variable region and the heavy chain variable region include three variable regions called “complementarity determining region” (hereinafter referred to as "CDR") and four "framework regions”.
- CDRs mainly play a role in binding to the epitope of the antigen.
- the CDRs of each chain typically start from the N-terminus and are sequentially referred to as CDR1, CDR2, and CDR3, and are also identified by the chain in which the specific CDR is located.
- heavy chain refers to a full-length heavy chain comprising a variable region domain V H and three constant region domains C H1 , C H2 and C H3 comprising an amino acid sequence having a sufficient variable region sequence to confer antigen specificity. And fragments thereof.
- light chain refers to both a full-length light chain including a variable region domain V L and a constant region domain C L comprising an amino acid sequence having a sufficient variable region sequence to confer antigen specificity and a fragment thereof.
- variable is used to refer to that the sequence of a specific region is significantly different between antibodies and is used to indicate the binding specificity of each specific antibody for a specific antigen.
- the variability of an antibody is not uniformly distributed throughout the variable domain of the antibody, but rather is concentrated in the CDRs.
- the heavy and light chains of a monoclonal antibody each have three CDRs, and these regions form an antigen-antibody complex by recognizing the surface antigen of acne bacteria.
- Each of these CDRs has a characteristic sequence for each monoclonal antibody, and some or all of these six CDRs may interact in order for one monoclonal antibody to recognize a specific epitope.
- phage display technology refers to a technique for selecting antibodies that exhibit antigen-binding ability by selecting only phages that exhibit significant binding ability with a target antigen from a phage library.
- panning refers to a peptide having the property of binding to a target molecule (antibody, enzyme, cell surface receptor, etc.) from a phage library that displays the peptide on the coat of the phage. It refers to the process of selecting only the phages that are present. By repeating this process 3 to 10 times, an antibody that exhibits significant binding ability to a target antigen can be selected, and the selected antibody can be prepared as a humanized monoclonal antibody.
- the monoclonal antibody of the present invention may include a variant of the amino acid sequence described in the appended sequence listing within a range capable of specifically binding to YKL-40.
- the amino acid sequence of the monoclonal antibody can be changed to improve the binding affinity and/or other biological properties of the monoclonal antibody.
- Such modifications include, for example, deletions, insertions and/or substitutions of amino acid sequence residues of monoclonal antibodies.
- These amino acid variations are made based on the relative similarity of amino acid side chain substituents, such as hydrophobicity, hydrophilicity, charge, size, and the like.
- arginine, lysine and histidine are all positively charged residues; Alanine, glycine and serine have similar sizes; It can be seen that phenylalanine, tryptophan and tyrosine have similar shapes. Thus, based on these considerations, arginine, lysine and histidine; Alanine, glycine and serine; And phenylalanine, tryptophan and tyrosine are biologically functional equivalents. In introducing mutations, the hydropathy index of amino acids can be considered.
- Each amino acid is assigned a hydrophobicity index according to its hydrophobicity and charge: isoleucine (+4.5); Valine (+4.2); Leucine (+3.8); Phenylalanine (+2.8); Cysteine/cysteine (+2.5); Methionine (+1.9); Alanine (+1.8); Glycine (-0.4); Threonine (-0.7); Serine (-0.8); Tryptophan (-0.9); Tyrosine (-1.3); Proline (-1.6); Histidine (-3.2); Glutamate (-3.5); Glutamine (-3.5); Aspartate (-3.5); Asparagine (-3.5); Lysine (-3.9); And arginine (-4.5).
- the hydrophobic amino acid index is very important in imparting an interactive biological function of a protein.
- the most commonly occurring exchanges are amino acid residues Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Thy/Phe, Ala/ It is an exchange between Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, Asp/Gly.
- the monoclonal antibody of the present invention or a nucleic acid molecule encoding the same is interpreted to include a sequence showing substantial identity to the sequence listed in the Sequence Listing.
- the actual identity of the above is at least 61% when the sequence of the present invention and any other sequence described above are aligned to correspond as much as possible, and the aligned sequence is analyzed using an algorithm commonly used in the art. It means a sequence that exhibits homology, more preferably 70% homology, even more preferably 80% homology, and most preferably 90% homology.
- nucleic acid molecule has a meaning that comprehensively includes DNA (gDNA and cDNA) and RNA molecules, and the nucleotide, which is the basic structural unit in the nucleic acid molecule, is not only a natural nucleotide, but also a sugar or base moiety. Also includes modified analogues (Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhlman and Peyman, Chemical Reviews, 90:543-584 (1990)). The base sequence of the nucleic acid molecule encoding the heavy chain variable region and the light chain variable region of the monoclonal antibody of the present invention may be modified. Such modifications include additions, deletions or non-conservative substitutions or conservative substitutions of nucleotides.
- the vector produced in the present invention is constructed to be able to express a desired gene in a host cell.
- promoters and terminators operably linked to upstream and downstream of the vector are located, respectively.
- promoter refers to a DNA sequence that controls the expression of a coding sequence or functional RNA.
- the target nucleotide sequence is operably linked to the promoter.
- operatively linked refers to a functional linkage between a nucleic acid expression control sequence (eg, a promoter sequence, a signal sequence, or an array of transcriptional regulatory factor binding sites) and another nucleic acid sequence. Means, whereby the control sequence controls the transcription and/or translation of the other nucleic acid sequence.
- a nucleic acid expression control sequence eg, a promoter sequence, a signal sequence, or an array of transcriptional regulatory factor binding sites
- the vector system of the present invention can be constructed through various methods known in the art, and specific methods for this are disclosed in Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001).
- the vectors of the present invention can typically be constructed as vectors for expression.
- the method of transporting the vector of the present invention into a transformant host cell is a heat shock method, a CaCl 2 method (Cohen, SN et al., Proc. Natl. Acac. Sci. USA, 9:2110-2114 (1973)). , Hanahan method (Cohen, SN et al., Proc. Natl. Acac. Sci. USA, 9:2110-2114 (1973); And Hanahan, D., J. Mol. Biol., 166:557-580 ( 1983)) and an electroporation method (Dower, WJ et al., Nucleic. Acids Res., 16:6127-6145 (1988)).
- the pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier.
- pharmaceutically acceptable means exhibiting properties that are not toxic to cells or humans exposed to the composition.
- the carrier may be used without limitation as long as it is known in the art such as a buffering agent, a preservative, a painless agent, a solubilizing agent, an isotonic agent, a stabilizer, a base agent, an excipient, and a lubricant.
- the pharmaceutical composition of the present invention is formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injectable solutions according to a conventional method.
- oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc.
- external preparations suppositories
- sterile injectable solutions according to a conventional method.
- it may be used in the form of an ointment, lotion, spray, patch, cream, powder, suspension, gel or gel for external skin.
- Carriers, excipients and diluents that may be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oils.
- diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants that are usually used.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient, such as starch, calcium carbonate, in the Cycotria rubra extract, It is prepared by mixing sucrose or lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
- Liquid preparations for oral use include suspensions, liquid solutions, emulsions, syrups, etc.In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweetening agents, fragrances, and preservatives may be included. have.
- Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations, and suppositories.
- non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used.
- injectable ester such as ethyl oleate
- a base for suppositories witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used.
- the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
- administration means introducing a predetermined substance to an individual by an appropriate method, and the route of administration of the composition may be administered through any general route as long as it can reach the target tissue.
- Intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, and rectal administration may be administered, but are not limited thereto.
- the term "individual” refers to all animals including humans, such as rats, mice, and domestic animals. Preferably, it may be a mammal including a human.
- pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment and not cause side effects, and the effective dose level is the sex, age, and Weight, health condition, type of disease, severity, activity of the drug, sensitivity to the drug, method of administration, time of administration, route of administration, and rate of excretion, duration of treatment, factors including drugs used in combination or concurrently, and other fields of medicine. It can be readily determined by a person skilled in the art according to well-known factors. Administration may be administered once a day at the recommended dosage, or may be divided several times.
- YKL-40 (Chitinase-3-like protein 1) is a secreted glycoprotein of about 40 kDa encoded by the CHI3L1 gene, and is known to be expressed and secreted in various cells such as macrophages.
- YKL-40 plays an important role in the proliferation, survival, and metastasis of cancer cells.
- Antibodies against YKL-40 were selected for antibodies exhibiting significant binding ability with human YKL-40 (hYKL-40) through phage display technology (FIGS. 1A to 1D ). The binding ability with hYKL-40 was confirmed through ELISA for hYKL-40 phage. Briefly, hYKL-40 antigen was fixed at 30 ng per well, and the antigen-fixed well was blocked with MPBS (5% skim milk in PBS), and then reacted by adding hYKL-40 phage and mYKL-40 phage. .
- clones having 7 antibodies against hYKL-40 were selected from the Fab-I library and the Fab-II library, and no clones were formed in the scFv library (FIGS. 2A and 2B ).
- Two clones in the Fab-I library were described as 3A10-F1 (H1) and 3B12-F1 (H2), and the five clones in the KFab-II library were 3A11-F2 (H3), 3B7-F2 (H4), respectively. It was described as 3D12-F2 (H5), 3E12-F2 (H6) and 3G7-F2 (H7).
- mYKL-40 antibodies showing significant binding ability with mouse YKL-40 (mYKL-40) were selected (FIGS. 3A to 3D ), and the binding ability with mYKL-40 was confirmed through ELISA for mYKL-40 phage, simply mYKL- 40 antigens were fixed at 30 ng per well, and the wells to which the antigens were fixed were subjected to blocking treatment with MPBS (5% skim milk in PBS), followed by addition of hYKL-40 phage and mYKL-40 phage to react. In order to detect bound phage, after washing 4 times with PBST (0.05% Tween20 in PBS), Anti-M13-HRP (1:5,000) was added and reacted.
- MPBS 5% skim milk in PBS
- TMB (3,3',5,5'-Tetramethylbenzidine) substrate was added to induce a color development reaction, and 2N H2SO4 was added to terminate the reaction, and the absorbance of each well was measured at a wavelength of 450 nm. I did. As a result, 6 antibodies were selected from the Fab-II library, and no clones were formed in the Fab-I or scFv library (Fig. 4).
- the six clones in the Fab-II library were 4A12-F2 (M1), 4E12-F2 (M2), 4E3-F2 (M3), 4D10-F2 (M4), 4A7-F2 (M5) and 4A1-F2 (M6), respectively. ).
- the present inventors performed an experiment to convert the selected YKL-40 phage into an IgG form of a human antibody and verify it. Briefly, the selected YKL-40 phage were transfected into the Expi293 cell line and then cultured, and IgG was purified from 300 ml of the cell culture solution of the cultured Expi293 cell line. Purified IgG was confirmed for molecular weight and pure separation through SDS-PAGE.
- IgG was produced from 6 clones with hYKL-40 antibody, and 0.237 mg of IgG was finally produced in 3A10-F1 (H1), and 1.84 mg of IgG was finally produced in 3B12-F1 (H2).
- 3B7-F2 (H4) 6.5 mg of IgG was finally produced, 0.3 mg of IgG was produced in 3D12-F2 (H5), and 0.8 mg of IgG was finally produced in 3E12-F2 (H6).
- 3G7-F2 (H7) 5.3 mg of IgG was finally produced (FIGS. 5A to 5C ).
- the present inventors confirmed the presence of a single antibody through size-exclusion chromatography (SEC), and performed an experiment to measure antigen affinity through an EC50 value for each antibody through ELISA.
- SEC size-exclusion chromatography
- 3A10-F1 (H1), 3B12-F1 (H2), 3B7-F2 (H4), 3D12-F2 (H5), 3E12-F2 (H6) and 3G7-F2 (H7) are all single peaks in SEC. (peak) was found to be all monoantibodies (FIGS. 6A and 6B).
- the EC50 value in 3A10-F1 (H1) was 582 pM (0.582 nM), which was confirmed as the lowest EC50 value (FIG. 7).
- the present inventors performed the same experiment on the selected mouse YKL-40 phage. As a result, 1.6 mg of IgG was finally produced in 4E12-F2 (M2), 3.6 mg of IgG was finally produced in 4E3-F2 (M3), and 6.3 mg of IgG was finally produced in 4D10-F2 (M4). Was produced, and finally 0.7 mg of IgG was produced in 4A7-F2 (M5) (FIGS. 8A and 8B ).
- the present inventors to determine whether the clones 3A10-F1 (H1) and 4E3-F2 (M3), which showed the lowest EC50 values for hYKL-40 and mYKL-40, respectively, cross-link to hYKL-40 and mYKL-40.
- ELISA was performed using the Fab protein of each antibody.
- 3A10-F1 (H1) was found to bind only to hYKL-40
- 4E3-F2 (M3) was found to cross-link to hYKL-40 and mYKL-40 (FIGS. 11A and 11B ).
- the present inventors conducted an experiment to confirm whether there is an effect of inhibiting cancer metastasis when the candidate antibodies against YKL-40 are treated with a lung cancer cell line. Briefly, migration of the human lung cancer cell line A549 cell line and H460 cell line was quantitatively performed in a permeable insert (8 ⁇ m pore trans-well; Corning Inc.).
- HYKL-40 antibodies as candidate antibodies 3A10-F1 (H1), 3B12-F1 (H2), 3B7-F2 (H4), 3D12-F2 (H5), 3E12-F2 (H6) and 3G7-F2 (H7); And mYKL-40 antibodies 4E12-F2 (M2), 4E3-F2 (M3), 4D10-F2 (M4) and 4A7-F2 (M5) at a concentration of 1 ⁇ g/ml in the lung cancer cell lines A549 and H460 cells After treatment with, the A549 and H460 cells treated with the candidate antibodies were put so as to be 2.0 x 10 4 cells per well, respectively, and incubated for 17 hours in a humidified incubator at 37°C and 5% CO 2 conditions.
- the cells were fixed with 3.7% formaldehyde for 2 minutes, and then washed twice with 1x PBS. Thereafter, the cells were permeated with 100% methanol for 15 minutes and stained with trypan blue for 20 minutes. Unmigrated cells inside the wells were removed with a cotton swab, and images captured with an optical microscope (Olympus) at x 200 magnification were analyzed using NIH ImageJ software.
- the present inventors performed an experiment to confirm whether there is an effect of inhibiting cancer metastasis when the five candidate antibodies selected in the cell line experiment were treated in an animal model of lung metastasis. Briefly, B16F10 mouse melanoma cells (3.75x104 cells) per mouse were put in a tail vein injection method for lung metastasis, and then once a week for a total of 3 weeks, hYKL-40 antibody 3A10-F1 ( H1), 3B12-F1 (H2) and 3B7-F2 (H4); And mYKL-40 antibodies 4E12-F2 (M2) and 4E3-F2 (M3) were administered at 0.5 mg/kg. Three weeks after the administration of melanoma cells, the lungs were excised and the tumor area on the lung surface was measured.
- 3A10-F1 (H1) and 4E3-F2 (M3) increased the number of experimental animals to confirm whether there is an effect of inhibiting cancer metastasis.
- the experiment was carried out.
- both 3A10-F1 (H1) and 4E3-F2 (M3) reduced the number of tumor nodules on the surface of the lung tissue compared to the control group, thereby inhibiting the metastasis of lung cancer.
- 3A10-F1 It was confirmed that the (H1) antibody has the most remarkable effect of suppressing the number of tumor nodules (FIGS. 16A to 16C ).
- the present inventors analyzed the sequences of the 3A10-F1 (H1) antibody and 4E3-F2 (M3) antibody that are effective in inhibiting cancer.
- the amino acid sequence of the heavy chain variable region for the 3A10-F1 (H1) antibody and the 4E3-F2 (M3) antibody is shown in Table 1 below, and the amino acid sequence of the light chain variable region is shown in Table 2.
- the amino acid sequences of CDR1 to CDR3 in the heavy chain variable region are shown in Table 3 below, and the amino acid sequences of CDR1 to CDR3 in the light chain variable region are shown in Table 4 below.
- the base sequence of the heavy chain variable region for the nucleic acid molecule encoding the antibody is shown in Table 5 below, and the base sequence of the light chain variable region is shown in Table 6 below.
- the nucleotide sequences encoding CDR1 to CDR3 in the heavy chain variable region are shown in Table 7 below, and the nucleotide sequences encoding CDR1 to CDR3 in the light chain variable region are shown in Table 8.
- Antibody Amino acid sequence of heavy chain variable region of antibody (CDR: underlined) 3A10-F1 (H1) EVQLVESGGGLVQPGGSLRLSCAASGFTFS NYAMS WVRQAPGKGLEWVS GISGSGGTTYYADSVKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAG VGTFDV WGQGTLVTVSS (SEQ ID NO: 1) 4E3-F2 (M3) QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SYDIH WVRQAPGQGLEWMG IISPYLGITIYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR RYFYYQSEAFDY WGQGTLVTVSS (SEQ ID NO: 2)
- Antibody Amino acid sequence of antibody light chain variable region (CDR: underlined) 3A10-F1 (H1) DIQMTQSPSSLSASVGDRVTITC RASQTISSWLN WYQQKPGKAPKLLIY AASRLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSYSTPLT FGQGTKVEIK (SEQ ID NO: 3) 4E3-F2 (M3) DIQMTQSPSSLSASVGDRVTITC RASQSISNYLN WYQQKPGKAPKLLIY AASTLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSYSFPLT FGQGTKVEIK (SEQ ID NO: 4)
- Antibody CDRH1 CDRH2 CDRH3 3A10-F1 NYAMS (SEQ ID NO: 5) GISGSGGTTYYADSVKG (SEQ ID NO: 6) VGTFDV (SEQ ID NO: 7) 4E3-F2 (M3) SYDIH (SEQ ID NO: 8) IISPYLGITIYAQKFQG (SEQ ID NO: 9) RYFYYQSEAFDY (SEQ ID NO: 10)
- Antibody CDRL1 CDRL2 CDRL3 3A10-F1 H1 RASQTISSWLN (SEQ ID NO: 11) AASRLQS (SEQ ID NO: 12) QQSYSTPLT (SEQ ID NO: 13) 4E3-F2 (M3) RASQSISNYLN (SEQ ID NO: 14) AASTLQS (SEQ ID NO: 15) QQSYSFPLT (SEQ ID NO: 16)
- Antibody Base sequence of heavy chain variable region of antibody (CDR: underlined) 3A10-F1 (H1) GAAGTACAGTTGGTCGAAAGTGGCGGTGGCCTCGTGCAACCGGGTGGTTCACTGCGTCTGAGCTGCGCCGCCTCGGGTTTTACTTTCTCT AATTATGCAATGTCT TGGGTTCGTCAGGCGCCGGGCAAGGGTCTCGAATGGGTTTCA GGTATCTCTGGTTCTGGTGGTACTACTTACTATGCCGATTCAGTGAAGGGT CGCTTTACCATTTCCCGTGACAACTCTAAGAATACTCTGTATCTGCAGATGAACTCGCTGCGTGCCGAAGACACGGCCGTCTATTATTGCCGGT GTTGGTACTTTCGATGTT TGGGGTCAGGGCACTTTAGTGACCGTCTCATCG (SEQ ID NO: 17) 4E3-F2 (M3) CAAGTTCAGCTGGTCCAGAGCGGCGCAGAGGTGAAGAAGCCCGGCAGTTCTGTTAAGGTTTCCTGCAAAGCCTCAGGCG
- Antibody Base sequence of the light chain variable region of the antibody (CDR: underlined) 3A10-F1 (H1) GACATTCAAATGACGCAGAGTCCCTCCTCACTGAGTGCTAGCGTGGGCGATCGTGTGACAATTACTTGT CGCGCTAGCCAGACTATCTCTTCTTGGCTGAAC TGGTATCAGCAGAAACCGGGCAAGGCGCCAAAATTGCTGATTTAC GCAGCATCCCGTCTGCAGTCT GGTACCGTCCCGTTTCTCTGGCAGCGGTTCTGGTACGGATTTTACCCTGACCATCTCAAGCCTCCAGCCTGAAGATTTTGCCACCTATTATTGT CAGCAATCTTACTCTACTCCGCTGACG TTCGGGCAGGGAACTAAAGTGGAAATTAAA (SEQ ID NO: 19) 4E3-F2 (M3) GACATTCAAATGACGCAGAGTCCCTCCTCACTGAGTGCTAGCGTGGGCGATCGTGTGACAATTACTTGT CGCGCTAGCCAGTCTATCTAATTACCTGA
- Antibody CDRH1 CDRH2 CDRH3 3A10-F1 H1
- AATTATGCAATGTCT SEQ ID NO: 21
- GGTATCTCTGGTTCTGGTGGTACTACTTACTATGCCGATTCAGTGAAGGGT SEQ ID NO: 22
- GTTGGTACTTTCGATGTT SEQ ID NO: 23
- 4E3-F2 M3
- TCTTACGATATCCAT SEQ ID NO: 24
- ATCATTTCTCCATACCTGGGTATCACCATCTATGCACAAAAATTCCAAGGC SEQ ID NO: 25
- CGTTACTTCTACTACCAGTCTGAAGCATTCGATTAC SEQ ID NO: 26
- Antibody CDRL1 CDRL2 CDRL3 3A10-F1 H1 CGCGCTAGCCAGACTATCTCTTCTTGGCTGAAC (SEQ ID NO: 27) GCAGCATCCCGTCTGCAGTCT (SEQ ID NO: 28) CAGCAATCTTACTCTACTCCGCTGACG (SEQ ID NO: 29) 4E3-F2 (M3) CGCGCTAGCCAGTCTATCTCTAATTACCTGAAC (SEQ ID NO: 30) GCAGCATCCACTCTGCAGTCT (SEQ ID NO: 31) CAGCAATCTTACTCTTTTCCGCTGACG (SEQ ID NO: 32)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
항체 | 항체의 중쇄 가변영역의 아미노산 서열 (CDR: 밑줄) |
3A10-F1 (H1) | EVQLVESGGGLVQPGGSLRLSCAASGFTFS NYAMS WVRQAPGKGLEWVS GISGSGGTTYYADSVKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAG VGTFDV WGQGTLVTVSS (서열번호 1) |
4E3-F2 (M3) | QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SYDIH WVRQAPGQGLEWMG IISPYLGITIYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR RYFYYQSEAFDY WGQGTLVTVSS (서열번호 2) |
항체 | 항체의 경쇄 가변영역의 아미노산 서열 (CDR: 밑줄) |
3A10-F1 (H1) | DIQMTQSPSSLSASVGDRVTITC RASQTISSWLN WYQQKPGKAPKLLIY AASRLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSYSTPLT FGQGTKVEIK (서열번호 3) |
4E3-F2 (M3) | DIQMTQSPSSLSASVGDRVTITC RASQSISNYLN WYQQKPGKAPKLLIY AASTLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSYSFPLT FGQGTKVEIK (서열번호 4) |
항체 | CDRH1 | CDRH2 | CDRH3 |
3A10-F1 (H1) | NYAMS(서열번호 5) | GISGSGGTTYYADSVKG (서열번호 6) | VGTFDV(서열번호 7) |
4E3-F2 (M3) | SYDIH(서열번호 8) | IISPYLGITIYAQKFQG (서열번호 9) | RYFYYQSEAFDY (서열번호 10) |
항체 | CDRL1 | CDRL2 | CDRL3 |
3A10-F1 (H1) | RASQTISSWLN(서열번호 11) | AASRLQS(서열번호 12) | QQSYSTPLT(서열번호 13) |
4E3-F2 (M3) | RASQSISNYLN(서열번호 14) | AASTLQS(서열번호 15) | QQSYSFPLT(서열번호 16) |
항체 | 항체의 중쇄 가변영역의 염기 서열 (CDR: 밑줄) |
3A10-F1 (H1) | GAAGTACAGTTGGTCGAAAGTGGCGGTGGCCTCGTGCAACCGGGTGGTTCACTGCGTCTGAGCTGCGCCGCCTCGGGTTTTACTTTCTCT AATTATGCAATGTCT TGGGTTCGTCAGGCGCCGGGCAAGGGTCTCGAATGGGTTTCA GGTATCTCTGGTTCTGGTGGTACTACTTACTATGCCGATTCAGTGAAGGGT CGCTTTACCATTTCCCGTGACAACTCTAAGAATACTCTGTATCTGCAGATGAACTCGCTGCGTGCCGAAGACACGGCCGTCTATTATTGCGCCGGT GTTGGTACTTTCGATGTT TGGGGTCAGGGCACTTTAGTGACCGTCTCATCG (서열번호 17) |
4E3-F2 (M3) | CAAGTTCAGCTGGTCCAGAGCGGCGCAGAGGTGAAGAAGCCCGGCAGTTCTGTTAAGGTTTCCTGCAAAGCCTCAGGCGGGACTTTTAGT TCTTACGATATCCAT TGGGTGCGGCAGGCGCCCGGCCAGGGTCTCGAATGGATGGGG ATCATTTCTCCATACCTGGGTATCACCATCTATGCACAAAAATTCCAAGGC CGCGTAACTATTACCGCCGACGAATCAACCTCCACCGCCTACATGGAACTCAGCTCTCTGAGGTCAGAAGACACGGCCGTCTATTATTGCGCCAGA CGTTACTTCTACTACCAGTCTGAAGCATTCGATTAC TGGGGTCAGGGTACTCTGGTTACCGTCTCATCG (서열번호 18) |
항체 | 항체의 경쇄 가변영역의 염기 서열 (CDR: 밑줄) |
3A10-F1 (H1) | GACATTCAAATGACGCAGAGTCCCTCCTCACTGAGTGCTAGCGTGGGCGATCGTGTGACAATTACTTGT CGCGCTAGCCAGACTATCTCTTCTTGGCTGAAC TGGTATCAGCAGAAACCGGGCAAGGCGCCAAAATTGCTGATTTAC GCAGCATCCCGTCTGCAGTCT GGTGTACCGTCCCGTTTCTCTGGCAGCGGTTCTGGTACGGATTTTACCCTGACCATCTCAAGCCTCCAGCCTGAAGATTTTGCCACCTATTATTGT CAGCAATCTTACTCTACTCCGCTGACG TTCGGGCAGGGAACTAAAGTGGAAATTAAA (서열번호 19) |
4E3-F2 (M3) | GACATTCAAATGACGCAGAGTCCCTCCTCACTGAGTGCTAGCGTGGGCGATCGTGTGACAATTACTTGT CGCGCTAGCCAGTCTATCTCTAATTACCTGAAC TGGTATCAGCAGAAACCGGGCAAGGCGCCAAAATTGCTGATTTAC GCAGCATCCACTCTGCAGTCT GGTGTACCGTCCCGTTTCTCTGGCAGCGGTTCTGGTACGGATTTTACCCTGACCATCTCAAGCCTCCAGCCTGAAGATTTTGCCACCTATTATTGT CAGCAATCTTACTCTTTTCCGCTGACG TTCGGGCAGGGAACTAAAGTGGAAATTAAA (서열번호 20) |
항체 | CDRH1 | CDRH2 | CDRH3 |
3A10-F1 (H1) | AATTATGCAATGTCT(서열번호 21) | GGTATCTCTGGTTCTGGTGGTACTACTTACTATGCCGATTCAGTGAAGGGT(서열번호 22) | GTTGGTACTTTCGATGTT(서열번호 23) |
4E3-F2 (M3) | TCTTACGATATCCAT (서열번호 24) | ATCATTTCTCCATACCTGGGTATCACCATCTATGCACAAAAATTCCAAGGC(서열번호 25) | CGTTACTTCTACTACCAGTCTGAAGCATTCGATTAC(서열번호 26) |
항체 | CDRL1 | CDRL2 | CDRL3 |
3A10-F1 (H1) | CGCGCTAGCCAGACTATCTCTTCTTGGCTGAAC(서열번호 27) | GCAGCATCCCGTCTGCAGTCT(서열번호 28) | CAGCAATCTTACTCTACTCCGCTGACG(서열번호 29) |
4E3-F2 (M3) | CGCGCTAGCCAGTCTATCTCTAATTACCTGAAC(서열번호 30) | GCAGCATCCACTCTGCAGTCT(서열번호 31) | CAGCAATCTTACTCTTTTCCGCTGACG(서열번호 32) |
Claims (17)
- YKL-40 에 특이적으로 결합하는 단일클론항체.
- 제 1 항에 있어서,상기 단일클론항체는 하기의 영역을 포함하는 것을 특징으로 하는 단일클론항체:(a) 서열번호 5의 아미노산 서열로 이루어진 CDR1; 서열번호 6의 아미노산 서열로 이루어진 CDR2; 및 서열번호 7의 아미노산 서열로 이루어진 CDR3을 포함하는 중쇄 가변영역; 및(b) 서열번호 11의 아미노산 서열로 이루어진 CDR1; 서열번호 12의 아미노산 서열로 이루어진 CDR2; 및 서열번호 13의 아미노산 서열로 이루어진 CDR3을 포함하는 경쇄 가변영역.
- 제 1 항에 있어서,상기 단일클론항체는 하기의 영역을 포함하는 것을 특징으로 하는 단일클론항체:(a) 서열번호 8의 아미노산 서열로 이루어진 CDR1; 서열번호 9의 아미노산 서열로 이루어진 CDR2; 및 서열번호 10의 아미노산 서열로 이루어진 CDR3을 포함하는 중쇄 가변영역; 및(b) 서열번호 14의 아미노산 서열로 이루어진 CDR1, 서열번호 15의 아미노산 서열로 이루어진 CDR2; 및 서열번호 16의 아미노산 서열로 이루어진 CDR3을 포함하는 경쇄 가변영역.
- 제 1 항에 있어서,상기 단일클론항체는 하기의 영역을 포함하는 것을 특징으로 하는 단일클론항체:(a) 서열번호 1의 아미노산 서열로 이루어진 중쇄 가변영역; 및(b) 서열번호 3의 아미노산 서열로 이루어진 경쇄 가변영역.
- 제 1 항에 있어서,상기 단일클론항체는 하기의 영역을 포함하는 것을 특징으로 하는 단일클론항체:(a) 서열번호 2의 아미노산 서열로 이루어진 중쇄 가변영역; 및(b) 서열번호 4의 아미노산 서열로 이루어진 경쇄 가변영역.
- 제 1 항에 있어서,상기 단일클론항체는 인간화 항체인 것을 특징으로 하는 단일클론항체.
- 제 1 항의 단일클론항체를 코딩하는 핵산분자.
- 제 7 항에 있어서,상기 핵산분자는 하기의 영역을 포함하는 것을 특징으로 하는 핵산분자.(a) 서열번호 21의 염기서열로 이루어진 CDR1; 서열번호 22의 염기서열로 이루어진 CDR2; 및 서열번호 23의 염기서열로 이루어진 CDR3을 포함하는 중쇄 가변영역; 및(b) 서열번호 27의 염기서열로 이루어진 CDR1; 서열번호 28의 염기서열로 이루어진 CDR2; 및 서열번호 29의 염기서열로 이루어진 CDR3을 포함하는 경쇄 가변영역.
- 제 7 항에 있어서,상기 핵산분자는 하기의 영역을 포함하는 것을 특징으로 하는 핵산분자.(a) 서열번호 24의 염기서열로 이루어진 CDR1; 서열번호 25의 염기서열로 이루어진 CDR2; 및 서열번호 26의 염기서열로 이루어진 CDR3을 포함하는 중쇄 가변영역; 및(b) 서열번호 30의 염기서열로 이루어진 CDR1; 서열번호 31의 염기서열로 이루어진 CDR2; 및 서열번호 32의 염기서열로 이루어진 CDR3을 포함하는 경쇄 가변영역.
- 제 7 항에 있어서,상기 핵산분자는 하기의 영역을 포함하는 것을 특징으로 하는 핵산분자.(a) 서열번호 17의 염기서열로 이루어진 중쇄 가변영역; 및(b) 서열번호 19의 염기서열로 이루어진 경쇄 가변영역.
- 제 7 항에 있어서,상기 핵산분자는 하기의 영역을 포함하는 것을 특징으로 하는 핵산분자.(a) 서열번호 18의 염기서열로 이루어진 중쇄 가변영역; 및(b) 서열번호 20의 염기서열로 이루어진 경쇄 가변영역.
- 제 7 항의 핵산분자를 포함하는 재조합 발현 벡터.
- 제 12 항의 재조합 발현 벡터로 형질전환된 형질전환체.
- 제 1 항의 단일클론항체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물.
- 제 14 항에 있어서,상기 암은 유방암, 대장암, 폐암, 위암, 간암, 혈액암, 골암, 췌장암, 피부암, 뇌암, 자궁암, 비인두암, 후두암, 두경부암, 결장암, 난소암, 직장암, 대장암, 질암, 소장암, 내분비암, 갑상선암, 부갑상선암, 요관암, 요도암, 전립선암, 기관지암, 방광암, 신장암 및 골수암으로 이루어진 군에서 선택되는 어느 하나인 것을 특징으로 하는 조성물.
- 제 1 항의 단일클론항체를 유효성분으로 포함하는 암의 진단용 조성물.
- 제 16 항에 있어서,상기 암은 유방암, 대장암, 폐암, 위암, 간암, 혈액암, 골암, 췌장암, 피부암, 뇌암, 자궁암, 비인두암, 후두암, 두경부암, 결장암, 난소암, 직장암, 대장암, 질암, 소장암, 내분비암, 갑상선암, 부갑상선암, 요관암, 요도암, 전립선암, 기관지암, 방광암, 신장암 및 골수암으로 이루어진 군에서 선택되는 어느 하나인 것을 특징으로 하는 조성물.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022516421A JP7340895B2 (ja) | 2019-09-11 | 2020-09-07 | Ykl-40標的ヒト単一クローン抗体 |
US17/753,682 US20220340649A1 (en) | 2019-09-11 | 2020-09-07 | Ykl-40-targeting human monoclonal antibody |
BR112022004408A BR112022004408A2 (pt) | 2019-09-11 | 2020-09-07 | Anticorpo monoclonal humano alvejando ykl-40 |
EP20862449.4A EP4029878A4 (en) | 2019-09-11 | 2020-09-07 | HUMAN MONOCLONAL ANTIBODY TARGETING YKL-40 |
CA3150907A CA3150907A1 (en) | 2019-09-11 | 2020-09-07 | Ykl-40-targeting human monoclonal antibody |
CN202080077448.7A CN114641492A (zh) | 2019-09-11 | 2020-09-07 | 靶向ykl-40的人类单克隆抗体 |
AU2020347018A AU2020347018A1 (en) | 2019-09-11 | 2020-09-07 | YKL-40-targeting human monoclonal antibody |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190112572A KR102142499B1 (ko) | 2019-09-11 | 2019-09-11 | Ykl-40 표적 인간 단일클론항체 |
KR10-2019-0112572 | 2019-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021049830A1 true WO2021049830A1 (ko) | 2021-03-18 |
Family
ID=72049384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/012036 WO2021049830A1 (ko) | 2019-09-11 | 2020-09-07 | Ykl-40 표적 인간 단일클론항체 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220340649A1 (ko) |
EP (1) | EP4029878A4 (ko) |
JP (1) | JP7340895B2 (ko) |
KR (1) | KR102142499B1 (ko) |
CN (1) | CN114641492A (ko) |
AU (1) | AU2020347018A1 (ko) |
BR (1) | BR112022004408A2 (ko) |
CA (1) | CA3150907A1 (ko) |
WO (1) | WO2021049830A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117024586A (zh) * | 2023-08-22 | 2023-11-10 | 艾可泰科(浙江)控股有限公司 | 一种抗体组合物及应用于检测血液中ykl-40浓度的方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102142499B1 (ko) * | 2019-09-11 | 2020-08-10 | 재단법인 오송첨단의료산업진흥재단 | Ykl-40 표적 인간 단일클론항체 |
KR20230011064A (ko) * | 2021-07-13 | 2023-01-20 | 충북대학교 산학협력단 | Chi3L1에 특이적인 인간화 단일클론항체를 포함하는 대식세포의 M2 분극화 억제 및 암의 치료용 조성물 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
JP2008531608A (ja) * | 2005-02-28 | 2008-08-14 | バイオ−イー アー/エス | Ykl−40モノクローナル抗体 |
US7670599B2 (en) | 1993-07-09 | 2010-03-02 | The Regents Of The University Of California | YKL-40 as a marker and prognostic indicator for cancers |
US20190002586A1 (en) * | 2017-01-05 | 2019-01-03 | Brown University | Methods and compositions relating to anti-chi3l1 antibody reagents |
KR102142499B1 (ko) * | 2019-09-11 | 2020-08-10 | 재단법인 오송첨단의료산업진흥재단 | Ykl-40 표적 인간 단일클론항체 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1127351C (zh) * | 1993-09-02 | 2003-11-12 | 达特茅斯学院理事 | 诱导抗原特异性t细胞耐受的方法 |
CA3076241A1 (en) * | 2017-09-21 | 2019-03-28 | Yale University | Anti-ykl40 antibodies and methods of use |
-
2019
- 2019-09-11 KR KR1020190112572A patent/KR102142499B1/ko active IP Right Grant
-
2020
- 2020-09-07 JP JP2022516421A patent/JP7340895B2/ja active Active
- 2020-09-07 CA CA3150907A patent/CA3150907A1/en active Pending
- 2020-09-07 WO PCT/KR2020/012036 patent/WO2021049830A1/ko unknown
- 2020-09-07 CN CN202080077448.7A patent/CN114641492A/zh active Pending
- 2020-09-07 EP EP20862449.4A patent/EP4029878A4/en active Pending
- 2020-09-07 AU AU2020347018A patent/AU2020347018A1/en active Pending
- 2020-09-07 US US17/753,682 patent/US20220340649A1/en active Pending
- 2020-09-07 BR BR112022004408A patent/BR112022004408A2/pt unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US7670599B2 (en) | 1993-07-09 | 2010-03-02 | The Regents Of The University Of California | YKL-40 as a marker and prognostic indicator for cancers |
US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
JP2008531608A (ja) * | 2005-02-28 | 2008-08-14 | バイオ−イー アー/エス | Ykl−40モノクローナル抗体 |
US20190002586A1 (en) * | 2017-01-05 | 2019-01-03 | Brown University | Methods and compositions relating to anti-chi3l1 antibody reagents |
KR102142499B1 (ko) * | 2019-09-11 | 2020-08-10 | 재단법인 오송첨단의료산업진흥재단 | Ykl-40 표적 인간 단일클론항체 |
Non-Patent Citations (7)
Title |
---|
COHEN, S.N. ET AL., PROC. NATL. ACAC. SCI. USA, vol. 9, 1973, pages 2110 - 2114 |
DOWER, W.J. ET AL., NUCLEIC. ACIDS RES., vol. 16, 1988, pages 6127 - 6145 |
H. NEURATHR.L. HILL: "The Proteins", 1979, ACADEMIC PRESS |
HANAHAN, D., J. MOL. BIOL., vol. 166, 1983, pages 557 - 580 |
SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS |
SCHEIT: "Nucleotide Analogs", 1980, JOHN WILEY |
UHLMANPEYMAN, CHEMICAL REVIEWS, vol. 90, 1990, pages 543 - 584 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117024586A (zh) * | 2023-08-22 | 2023-11-10 | 艾可泰科(浙江)控股有限公司 | 一种抗体组合物及应用于检测血液中ykl-40浓度的方法 |
CN117024586B (zh) * | 2023-08-22 | 2024-03-08 | 艾可泰科(浙江)控股有限公司 | 一种抗体组合物及应用于检测血液中ykl-40浓度的方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2020347018A1 (en) | 2022-04-14 |
US20220340649A1 (en) | 2022-10-27 |
BR112022004408A2 (pt) | 2022-07-05 |
CN114641492A (zh) | 2022-06-17 |
CA3150907A1 (en) | 2021-03-18 |
EP4029878A1 (en) | 2022-07-20 |
JP2022549090A (ja) | 2022-11-24 |
JP7340895B2 (ja) | 2023-09-08 |
EP4029878A4 (en) | 2023-08-30 |
KR102142499B1 (ko) | 2020-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021049830A1 (ko) | Ykl-40 표적 인간 단일클론항체 | |
WO2020076105A1 (ko) | 신규 항-c-kit 항체 | |
CN106456766B (zh) | 抗免疫原性糖肽的抗体、包含其的组合物及其用途 | |
EP2718323B1 (en) | HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING BETA-KLOTHO AND AN FGFR1c | |
US7619069B2 (en) | Antibodies to TGF-beta 1 | |
EP2361934A2 (en) | Hepatocyte growth factor (HGF) binding proteins | |
MX2012006467A (es) | PROTEINAS DE ENLACE A ANTIGENOS HUMANAS QUE ENLAZAN ß-KLOTHO, RECEPTORES FGF Y COMPLEJOS DE LOS MISMOS. | |
WO2011130417A2 (en) | HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS | |
KR101739489B1 (ko) | 인간 유래 항-인간 표피 생장인자 수용체 항체 및 그의 코딩 유전자와 용도 | |
WO2011030935A1 (en) | Antibodies against glucagon receptor and their use | |
WO2018237338A1 (en) | ANTI-ALPHA-SYNCUCIN ANTIBODIES AND METHODS OF USE | |
WO2016085289A1 (ko) | B형 간염 바이러스의 pres1에 특이적으로 결합하는 항체 및 이의 용도 | |
WO2016089126A1 (ko) | 뉴로필린 1(Neuropilin 1)에 대한 항체 및 이의 용도 | |
WO2017074013A1 (ko) | 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도 | |
WO2019096219A1 (zh) | 一种人源化抗il-13抗体及其制备方法和应用 | |
WO2016084993A1 (ko) | 신규 EGFRvIII 항체 및 이를 포함하는 조성물 | |
KR101854529B1 (ko) | 인간 및 마우스 Sema3A에 교차결합하는 항체 및 그의 용도 | |
US5730981A (en) | Monoclonal anti-ganglioside antibody and its preparation | |
EP4257195A2 (en) | Anti-cfae antibodies and methods of use | |
WO2022005068A1 (ko) | Lgals3bp에 특이적으로 결합하는 항체 및 이의 용도 | |
WO2017142294A1 (ko) | EGFRvIII에 대한 항체 및 이의 용도 | |
WO2019035630A2 (ko) | 인간 상피 성장 인자 수용체 변이체 ⅲ에 결합하는 항체 및 그의 항체 단편 | |
WO2020209559A1 (ko) | Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 | |
KR20160138312A (ko) | Vegfr2/ang2 화합물 | |
AU2014250730B2 (en) | Human antigen binding proteins that bind beta-Klotho, FGF receptors and complexes thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20862449 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3150907 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022516421 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022004408 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020347018 Country of ref document: AU Date of ref document: 20200907 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020862449 Country of ref document: EP Effective date: 20220411 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112022004408 Country of ref document: BR Free format text: COM BASE NA PORTARIA 56 DE 27/12/2021, SOLICITA-SE QUE SEJA APRESENTADO, EM ATE 60 (SESSENTA) DIAS, NOVO CONTEUDO DE LISTAGEM DE SEQUENCIA POIS O CONTEUDO APRESENTADO NA PETICAO NO 870220037590 DE 02/05/2022 NAO CORRESPONDE AO PEDIDO EM QUESTAO. CAMPOS 110 E 150 ESTAO DIVERGENTES. |
|
ENP | Entry into the national phase |
Ref document number: 112022004408 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220310 |